Real-World study tracks Zanubrutinib's impact on blood cancers
NCT ID NCT05326308
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This study follows 705 adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma who are taking zanubrutinib (with or without obinutuzumab) as part of their normal care. Researchers will track hospital visits, quality of life, and how well the treatment works in real-world settings. The goal is to fill gaps in knowledge about medical resource use and patient outcomes outside of clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lübecker Onkologische Schwerpunktpraxis
RECRUITINGLübeck, Schleswig-Holstein, D-23562, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsklinikum Salzburg, Klinik für Innere Medizin III
RECRUITINGSalzburg, A-5020, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib (Brukinsa) and obinutuzumab (Gazyvaro)
What this could lead to
If successful, this study could show how well zanubrutinib works in real-world settings and help doctors make better treatment decisions for these blood cancers.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient differences and real-world variability.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.